According to IMARC Group’s latest research report, titled “Immune Checkpoint Inhibitors Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” presents a comprehensive analysis of the industry, covering immune checkpoint inhibitors market size, trends, demand, and growth prospects. The report also provides competitor and regional analysis and showcases the contemporary advancements in the global market.
How big is the Immune Checkpoint Inhibitors Market?
The global immune checkpoint inhibitors market size reached US$ 36.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 97.3 Billion by 2028, exhibiting a growth rate (CAGR) of 17.19% during 2023-2028.
What are Immune Checkpoint Inhibitors?
Immune checkpoint inhibitors represent drugs that are utilized for treating cancer by inhibiting specific proteins made by immune system cells. They are generally either used alone or in combination with other cancer treatments, including chemotherapy and radiation therapy, to improve outcomes. Immune checkpoint inhibitors assist in enhancing the quality of life for cancer patients by minimizing the symptoms of the disease and extending their survival. In line with this, they have a lower toxicity profile that leads to better tolerance and fewer side effects as compared to traditional chemotherapy. Immune checkpoint inhibitors target specific pathways in the immune system, which, in turn, enables a more targeted approach to cancer treatment.
Get Free Sample Copy of Report at – https://www.imarcgroup.com/immune-checkpoint-inhibitors-market/requestsample
What are the Growth Prospects and Trends in the Immune Checkpoint Inhibitors Market?
The growing utilization of next-generation sequencing technologies that enable the identification of specific genetic mutations in cancer cells is primarily driving the immune checkpoint inhibitors market. Additionally, the rising incidences of respiratory disorders, on account of the widespread adoption of alcoholic beverages and tobacco-based products, are further bolstering the market growth. Besides this, the increasing number of clinical trials by pharmaceutical companies and the escalating demand for personalized medicines and new-generation drugs and formulations are acting as significant growth-inducing factors. Moreover, leading manufacturers are focusing on strategic collaborations and innovations to expand their product portfolio and gain a competitive edge, which is also positively influencing the global market. Apart from this, continuous improvements in medical infrastructures and diagnostic technologies and extensive investments in R&D activities are projected to fuel the immune checkpoint inhibitors market in the coming years.
Who are the key Players Operating in the Industry?
- AstraZeneca plc
- Bristol-Myers Squibb Company
- GSK plc
- Merck & Co. Inc.
- Ono Pharmaceutical Co. Ltd.
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Seagen Inc.
What is included in Market Segmentation?
The report has segmented the market into the following categories:
Type Insights:
- CTLA-4 Inhibitor
- PD-1 Inhibitor
- PD-L1 Inhibitor
Distribution Channel Insights:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Application Insights:
- Lung Cancer
- Bladder Cancer
- Melanoma
- Colorectal Cancer
- Hodgkin Lymphoma
- Others
Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
Key Highlights of the Report:
- Market Performance
- Market Outlook
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
Who we are:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800